: French vaccine maker Valneva launches Phase 3 trial of its COVID-19 shot after snubbing EU


Valneva’s Phase 3 trial will compare the immune response generated by its vaccine with that of the vaccine developed jointly by AstraZeneca and the University of Oxford

Need to Know: Goldman Sachs says S&P 500 returns may tumble as U.S. economic growth peaks. Buy these stocks.

Previous article

Commodities Corner: Here are the biggest risks to oil’s rally

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News